AbbVie, Thermo Fisher Scientific, Vertex Pharmaceuticals, BioNTech, Cencora, Danaher, and SpringWorks Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Error: Response status code does not indicate success: 429 (Too Many Requests). These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
ABBV traded up $5.59 during trading on Friday, hitting $185.96. 10,480,961 shares of the company's stock were exchanged, compared to its average volume of 6,064,215. The stock has a market cap of $328.96 billion, a P/E ratio of 77.48, a PEG ratio of 1.62 and a beta of 0.55. The business's 50 day moving average is $196.85 and its two-hundred day moving average is $187.23. AbbVie has a fifty-two week low of $153.58 and a fifty-two week high of $218.66. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94.
Read Our Latest Research Report on ABBV
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
NYSE TMO traded down $2.64 during trading hours on Friday, hitting $424.02. The company's stock had a trading volume of 2,698,284 shares, compared to its average volume of 1,742,311. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The company's 50-day simple moving average is $487.28 and its two-hundred day simple moving average is $527.66. The company has a market capitalization of $160.06 billion, a PE ratio of 25.65, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific has a 52 week low of $409.85 and a 52 week high of $627.88.
Read Our Latest Research Report on TMO
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Shares of VRTX stock traded up $1.37 during trading hours on Friday, reaching $493.84. The company had a trading volume of 1,561,491 shares, compared to its average volume of 1,334,761. The business has a fifty day simple moving average of $489.78 and a 200-day simple moving average of $466.36. Vertex Pharmaceuticals has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a market cap of $126.81 billion, a price-to-earnings ratio of -224.47, a price-to-earnings-growth ratio of 2.11 and a beta of 0.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35.
Read Our Latest Research Report on VRTX
BioNTech (BNTX)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Shares of BNTX stock traded down $18.52 on Friday, hitting $102.02. The stock had a trading volume of 6,438,309 shares, compared to its average volume of 897,110. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The business has a 50 day moving average of $101.72 and a 200 day moving average of $110.64. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The stock has a market cap of $24.48 billion, a price-to-earnings ratio of -48.58 and a beta of 1.07.
Read Our Latest Research Report on BNTX
Cencora (COR)
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
COR stock traded up $3.66 during mid-day trading on Friday, hitting $286.05. The company had a trading volume of 1,815,757 shares, compared to its average volume of 1,520,659. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The firm has a market cap of $55.47 billion, a PE ratio of 40.69, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55. The stock's fifty day moving average price is $268.09 and its two-hundred day moving average price is $249.16. Cencora has a 12 month low of $214.77 and a 12 month high of $296.65.
Read Our Latest Research Report on COR
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Danaher stock traded up $0.87 during midday trading on Friday, reaching $197.37. The stock had a trading volume of 2,608,666 shares, compared to its average volume of 3,352,400. The firm's 50-day moving average price is $200.87 and its 200 day moving average price is $224.58. The firm has a market capitalization of $141.06 billion, a PE ratio of 37.38, a P/E/G ratio of 2.66 and a beta of 0.86. Danaher has a 12 month low of $171.00 and a 12 month high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31.
Read Our Latest Research Report on DHR
SpringWorks Therapeutics (SWTX)
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
Shares of NASDAQ:SWTX traded down $0.21 during midday trading on Friday, reaching $44.72. 7,805,636 shares of the company traded hands, compared to its average volume of 1,467,102. The firm's fifty day moving average price is $46.20 and its two-hundred day moving average price is $40.50. The firm has a market capitalization of $3.35 billion, a price-to-earnings ratio of -12.85 and a beta of 0.79. SpringWorks Therapeutics has a 12 month low of $28.21 and a 12 month high of $62.00.
Read Our Latest Research Report on SWTX
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
